ArticleNPJ precision oncology2026
Deep learning inference of cell type-specific gene expression from breast tumor histopathology.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cell type-specific gene expression from single-cell RNA sequencing (RNA-seq) is valuable for breast cancer precision oncology but available cohorts are still limited due to its high cost. Deconvolution methods infer cell type-specific expression from bulk RNA-seq at a lower cost, yet expenses and processing time of bulk RNA-seq are also non-negligible and limit their application too. To address these limitations, we developed SLIDE-EX (SLide-based Inference of DEconvolved gene EXpression), a deep-learning framework that predicts cell type-specific gene expression and abundances directly from routine breast cancer histopathology whole slide images (WSIs), using deconvolved bulk RNA-seq data as training labels. Trained on the TCGA-breast cohort and tested in cross-validation and on an independent cohort of 160 cases, SLIDE-EX robustly infers the expression of thousands of genes across 9 distinct cell types, performing best for cancer-associated fibroblasts and cancer cells. The abundance of these two cell types could also be robustly predicted, together with that of myeloid cells. The robustly predicted genes reflect key biological functions of their respective cell types. From a translational perspective, the inferred cell-type-specific expression profiles predict chemotherapy response more accurately than models based on direct prediction from the slides or from the inferred bulk expression in two independent cohorts. Going forward, SLIDE-EX is a generic approach that opens up possibilities for rapid, cost-effective cell type-specific gene expression inference in potentially any cancer type, further democratizing the characterization of the tumor microenvironment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.